Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evaxion ASEVAX +0.08%48 Equity-to-Asset is 0.49 as of Jun. 2026, which is 29% above its 10-year median of 0.38. GuruFocus rates EVAX with a GF Score™ of 48/100 and a GF Value™ of $3.34 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, Evaxion AS ranks worse than 67.4% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Evaxion AS's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $9.53 Mil. Evaxion AS's Total Assets for the quarter that ended in Jun. 2026 was $19.38 Mil.
The historical rank and industry rank for Evaxion AS's Equity-to-Asset or its related term are showing as below:
EVAX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -7.52 Med: 0.38 Max: 0.87
Current: 0.49
During the past 9 years, the highest Equity to Asset Ratio of Evaxion AS was 0.87. The lowest was -7.52. And the median was 0.38.
EVAX's Equity-to-Asset is ranked worse than 67.4% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs EVAX: 0.49
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Evaxion AS Equity-to-Asset Related Terms
Evaxion AS Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Evaxion AS's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVAX vs DYAI, ATOS, PVCT: Equity-to-Asset Comparison
For the Biotechnology subindustry, Evaxion AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evaxion AS Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evaxion AS's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Evaxion AS's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Evaxion AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evaxion AS (EVAX) has a Equity-to-Asset of 0.49 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Evaxion AS and its competitors. This is 29% above median its historical median of 0.38. According to the industry distribution chart, Evaxion AS ranks #953 out of 1414 companies in the Biotechnology industry, placing it in the top 67.4%.
Is Evaxion AS's Equity-to-Asset too high?
Evaxion AS's current Equity-to-Asset of 0.49 is 29% above median its 10-year median of 0.38. The Biotechnology industry median Equity-to-Asset is 0.68. Evaxion AS's value of 0.49 is 27.9% below this industry median. Based on the distribution chart, Evaxion AS ranks #953 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Evaxion AS has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's Equity-to-Asset compare to DYAI and ATOS?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #953 out of 1414 companies for Equity-to-Asset. This places Evaxion AS in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Evaxion AS's value of 0.49 is 27.9% below this benchmark. While the company's 10-year median is 0.38 vs. the industry median of 0.68, Evaxion AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evaxion AS's current Equity-to-Asset of 0.49 is 27.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Evaxion AS and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evaxion AS's current Equity-to-Asset is 0.49, which is 29% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Based on GuruFocus' analysis, Evaxion AS (EVAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.34, compared to a current price of $3.13 — trading 6.3% below its estimated fair value. The current Equity-to-Asset is 0.49, which is 29% above median its 10-year median of 0.38 and 27.9% below the Biotechnology industry median of 0.68. Evaxion AS's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Evaxion AS (EVAX), the current Equity-to-Asset is 0.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evaxion AS (EVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Evaxion AS stock appears to be undervalued.
The current stock price of $3.13 is trading 6.3% below its estimated GF Value™ of $3.34.
GuruFocus considers Evaxion AS to be Fairly Valued.
Key valuation signals for EVAX:
Equity-to-Asset: 0.49 (29% above median its 10-year median of 0.38)
GF Value™: $3.34 vs. price of $3.13 (6.3% below fair value)
Industry Position: 27.9% below the Biotechnology median (#953 of 1414)
No single metric tells the full story. See the EVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
48GF Score
Get the complete analysis for EVAX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVAX has been successfully added to your 
